Pathological retinal neovascularization (RNV) is one of the leading causes of blindness worldwide; however, its underlying mechanism remains unclear. Here, we found that the expression of endothelial protein C receptor (Epcr) was increased during RNV, and its ligand was elevated in the serum or vitreous body of patients with proliferative diabetic retinopathy. Deleting endothelial Epcr or using an EPCR-neutralizing antibody ameliorated pathological retinal angiogenesis. EPCR promoted endothelial heme catabolism and carbon monoxide release through heme oxygenase 1 (HO-1). Inhibition of heme catabolism by deleting endothelial Ho-1 or using an HO-1 inhibitor suppressed pathological angiogenesis in retinopathy. Conversely, supplementation with carbon monoxide rescued the angiogenic defects after endothelial Epcr or Ho-1 deletion. Our results identified EPCR-dependent endothelial heme catabolism as an important contributor to pathological angiogenesis, which may serve as a potential target for treating vasoproliferative retinopathy.
Aims To explore the practice effect of establishing an integrated treatment process by stroke emergency nurses in general hospitals for acute ischaemic stroke (AIS). Design Compared the time spent in each link before and after the establishment of AIS integrated treatment. Methods Since March 2016, we set up a team of emergency stroke nurses (ESN), trained and assessed the knowledge of emergency stroke, and set up a post of ESN. Results The median time of admission-judgement, admission-establishment of venous access, admission-cranial CT examination and admission-intravenous thrombolytic therapy was statistically significantly shortened after the implementation of the integrated treatment process of AIS coordinated by stroke emergency nurses (p < .01). The new treatment process of AIS further shortens the time of each treatment link and promotes the timeliness.
Heat shock protein beta-1 may be involved in regulating ferroptosis in cells. The expression of heat shock protein beta-1 is upregulated after stroke; however, the underlying mechanism of action of heat shock protein beta-1 in cerebral ischemia/reperfusion injury remains unclear. Here, using both in vivo and in vitro models of ischemic injury-middle cerebral artery occlusion/reperfusion in C57BL/6J mice and oxygen-glucose deprivation/reoxygenation in BV-2 microglial cells-we observed that heat shock protein beta-1 overexpression significantly reduced infarct volume, mitigated neuronal loss, and improved neurological outcomes. Mechanistically, heat shock protein beta-1 attenuated lipid peroxidation, intracellular iron accumulation, and reactive oxygen species generation in microglia; this was accompanied by enhanced glutathione peroxidase 4 expression and suppressed nuclear factor-κB pathway activation. Notably, the pharmacological activation of nuclear factor-κB with phorbol 12-myristate 13-acetate reversed the protective effects of heat shock protein beta-1, confirming the functional relevance of this pathway. Together, our findings indicate that heat shock protein beta-1 exerts neuroprotective effects against cerebral ischemia/ reperfusion injury by suppressing microglial ferroptosis and pro-inflammatory activation via modulation of the nuclear factor-κB/glutathione peroxidase 4 signaling axis. These findings establish heat shock protein beta-1 as a critical regulator of the nuclear factor-κB/glutathione peroxidase 4 axis in microglia, thereby offering a dual-targeted strategy to inhibit ferroptosis and inflammation in ischemic stroke. Importantly, our study highlights heat shock protein beta-1 as a promising therapeutic candidate for preserving neurological function following cerebral ischemic injury.